Richard Wang has been named as chief executive of the joint venture, named Fosun Kite Biotechnology. Wang has extensive experience in the industry including roles at Procter & Gamble ...
Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback